TOP TEN perturbations for 39276_g_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39276_g_at
Selected probe(set): 243334_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39276_g_at (243334_at) across 6674 perturbations tested by GENEVESTIGATOR:
CNS cancer study 1 (PDX; glioma, malignant, NOS; primary) / CNS cancer study 1 (PDX; glioblastoma, NOS; primary)
Relative Expression (log2-ratio):3.0041704Number of Samples:2 / 3
Experimental | CNS cancer study 1 (PDX; glioma, malignant, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary glioma, malignant, NOS of the central nervous system (subcutaneously implanted). | |
Control | CNS cancer study 1 (PDX; glioblastoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary glioblastoma, NOS of the central nervous system (subcutaneously implanted). |
kidney transplantation study 9 (late) / normal kidney transplant
Relative Expression (log2-ratio):-2.6961346Number of Samples:2 / 13
Experimental | kidney transplantation study 9 (late) |
Human renal allograft biopsies from deceased donors obtained 24 months after transplantation. | |
Control | normal kidney transplant |
Human renal allograft biopsies from deceased donors obtained at implantation prior to revascularization. |
systemic lupus erythematosus study 13 (untreated) / normal PBMC sample
Relative Expression (log2-ratio):-2.4851036Number of Samples:4 / 5
Experimental | systemic lupus erythematosus study 13 (untreated) |
Peripheral blood mononuclear cells (PBMCs) obtained from systemic lupus erythematosus (SLE) patients. Freshly isolated PBMCs were cultured in RPMI/10% FBS for 6 hours. Lupus patients fulfilled American College of Rheumatology classification criteria for disease, and disease activity was quantified by SLEDAI. Patients were excluded if they showed symptoms of recent or active infection or were pregnant. None of the patients was taking Pioglitazone or other PPAR-γ agonists. | |
Control | normal PBMC sample |
Peripheral blood mononuclear cells (PBMCs) obtained from healthy subjects. Freshly isolated PBMCs were cultured in RPMI/10% FBS for 6 hours. |
endometriosis study 2 / normal endometrium tissue
Relative Expression (log2-ratio):-2.2831793Number of Samples:10 / 10
Experimental | endometriosis study 2 |
Endometrium tissue from patients with endometriosis. | |
Control | normal endometrium tissue |
Normal endometrium tissue. |
influenza virus study 9 (A/H9N2) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):-2.2815056Number of Samples:3 / 3
Experimental | influenza virus study 9 (A/H9N2) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/Duck/Malaysia/01 (H9N2). Samples were taken 10 hours post-infection. | |
Control | influenza virus study 4 (A/H1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-2.210638Number of Samples:13 / 2
Experimental | ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary serous cystadenocarcinoma, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
influenza virus study 10 (A/H5N2) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):-2.2007885Number of Samples:3 / 3
Experimental | influenza virus study 10 (A/H5N2) |
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F189/07/2004(H5N2). Samples were taken 10 hours post-infection. | |
Control | influenza virus study 4 (A/H1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
expO breast cancer study 1 (papillary carcinoma, NOS; primary) / expO breast cancer study 1 (metaplastic carcinoma, NOS; primary)
Relative Expression (log2-ratio):2.1944237Number of Samples:2 / 3
Experimental | expO breast cancer study 1 (papillary carcinoma, NOS; primary) |
Primary tumor tissue samples obtained from the breast of patients with papillary carcinoma (NOS). | |
Control | expO breast cancer study 1 (metaplastic carcinoma, NOS; primary) |
Primary tumor tissue samples obtained from the breast of patients with metaplastic carcinoma (NOS). |
expO breast cancer study 1 (papillary carcinoma, NOS; primary) / expO breast cancer study 1 (medullary carcinoma, NOS; primary)
Relative Expression (log2-ratio):2.1620073Number of Samples:2 / 2
Experimental | expO breast cancer study 1 (papillary carcinoma, NOS; primary) |
Primary tumor tissue samples obtained from the breast of patients with papillary carcinoma (NOS). | |
Control | expO breast cancer study 1 (medullary carcinoma, NOS; primary) |
Primary tumor tissue samples obtained from the breast of patients with medullary carcinoma (NOS). |
influenza virus study 9 (A/pH1N1) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):-2.1278229Number of Samples:3 / 3
Experimental | influenza virus study 9 (A/pH1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype [A/Singapore/478/2009 (pH1N1)]. Samples were taken 10 hours post-infection. | |
Control | influenza virus study 4 (A/H1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |